Pfizer stock: ELREXFIO trial win adds to oncology momentum
Published on 10/31/2026 at 10:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOncology Pipeline Gains Fresh Momentum
- The MagnetisMM-32 study met its primary progression-free-survival endpoint in relapsed or refractory multiple myeloma.
- Pfizer plans to submit the ELREXFIO findings to global health authorities.
- An Edison Scientific agreement will bring AI tools into Pfizer's research and development pipeline.
Pfizer said on Tuesday, October 27, that its Phase 3 MagnetisMM-32 study met its primary progression-free-survival endpoint in adults with relapsed or refractory multiple myeloma. The announcement strengthens the case for ELREXFIO in earlier treatment lines, although overall-survival results remain immature.
According to Pfizer's investor release, ELREXFIO reduced the risk of progression or death versus three established treatment regimens. More than 75 percent of patients receiving the medicine had not experienced progression or death at the interim analysis, with estimated progression-free survival of 68 percent at 18 months.
Clinical Progress Meets Safety Scrutiny
Pfizer plans to submit the findings to global health authorities and present detailed results at a future medical meeting. Investors will still weigh the immature overall-survival data and the infection profile: Grade 3 or higher infections occurred in 27.5 percent of patients receiving ELREXFIO, compared with 18.1 percent in the investigator-choice group.
A second company event arrived on Thursday, October 29. Yahoo Finance, carrying a Business Wire release, reported that Edison Scientific will deploy its AI platform and Kosmos across Pfizer's biopharmaceutical research and development pipeline. The collaboration covers oncology, internal medicine, immunology and other areas.
Stock Holds Near Recent Levels
Pfizer stock traded at 27.28 euros on Lang & Schwarz at 10:30 CET on Saturday, October 31, 0.22 percent below the Xetra close of Friday, October 30. Investors can follow the real-time quote of Pfizer stock as the market assesses the oncology pipeline and the company's upcoming quarterly update.
Pfizer Inc. stock
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Home exchange: New York Stock Exchange
- Lang & Schwarz quote: 27.28 euros on October 31, 2026, at 10:30 CET
- Daily comparison: 0.22 percent below the Xetra close of 27.34 euros on October 30, 2026
The broader US market remains the relevant backdrop for Pfizer stock; the S&P 500 provides the main benchmark for its home market.
